Retatrutide is an investigational triple hormone receptor agonist (targeting GLP-1, GIP, and glucagon receptors) developed by Eli Lilly for the treatment of obesity and type 2 diabetes.
Current clinical trials are evaluating its efficacy and safety for:
Obesity and overweight with weight-related medical conditions.
Type 2 diabetes management.
Metabolic dysfunction-associated steatotic liver disease (MASLD).
Knee osteoarthritis pain and chronic low back pain.
Obstructive sleep apnea (OSA) and cardiovascular/renal outcomes.
It is not yet FDA-approved and remains in Phase 3 clinical trials; consequently, it is not currently available for prescription.

Price:
Minimum Order Quantity : 100 Square Foots
Material : Metal Alloys
Surface Treatment : Coated